
The vaccine showed promise when used in combination with Merck & Co’s Keytruda

Nearly 325,000 new cases of melanoma were diagnosed globally in 2020

The vaccine in combination with Keytruda reduced the risk of recurrence or death by 44%

The vaccine is currently being evaluated as a treatment for high-risk melanoma patients

HER-Vaxx plus chemotherapy resulted in ORR of 50% compared to 29% for chemotherapy alone

The FDA initially approved Keytruda in 2017 for stomach cancer based on overall response rate data

FDA clears the drug as a third-line option after chemotherapy

Follows shortly after the drug's US approval in non-small cell lung cancer

Fails in phase III for breast cancer but better results for stomach cancer

Stimuvax unable to demonstrated improvement in overall survival